BioCardia (NASDAQ:BCDA) Announces Quarterly Earnings Results

Posted by Chris Copeland on Mar 27th, 2025

BioCardia (NASDAQ:BCDA – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.62, Zacks reports. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. During the same quarter in the prior year, the business earned ($8.19) EPS.

BioCardia Trading Up 0.0 %

BCDA stock opened at $2.55 on Thursday. The company has a market capitalization of $11.69 million, a price-to-earnings ratio of -0.61 and a beta of 1.28. The firm’s 50-day moving average is $2.44 and its two-hundred day moving average is $2.41. BioCardia has a 52 week low of $1.63 and a 52 week high of $6.41.

Insider Activity at BioCardia

In other news, Director Simon H. Stertzer purchased 22,753 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was acquired at an average price of $2.30 per share, with a total value of $52,331.90. Following the purchase, the director now owns 40,602 shares in the company, valued at $93,384.60. This represents a 127.47 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired a total of 25,353 shares of company stock valued at $58,525 over the last ninety days. Insiders own 20.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BCDA. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

Read Our Latest Stock Analysis on BioCardia

About BioCardia

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.